Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

1,264 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005, background): “We have not identified this mutation in 155 tumors (see above), and among nearly 1,300 lung cancers in which analysis of EGFR exons 18 to 21 has been performed [1,2,3,4,5,6], only one tumor (which also harbored an L858R mutation) was reported to contain the T790M mutation.”
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “However, it is noteworthy that the median follow-up period was short (788 days) (Kosaka et al., 2004).”
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, neutral): “Japan 9 [60, 61, 68, 69, 74, 76, 77, 80, 82] 549/829 66 57-83 326/919 35 26-54”
Lung cancer in never smokers — a different disease (2007, background): “EGFR mutations are the first specific genetic mutation associated with never smokers, and increasing smoke exposure is negatively correlated with mutatio”